SCHEMBL17442002

SCHEMBL17442002

CC(C)(C)OC(=O)N1CCN(c2ccc(-c3cnc4c(-c5cccc6c(C(=O)O)cccc56)cnn4c3)cc2)CC1

nearest known ligand 0.59

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
ACVR1 Q04771 12/20 0.59
BMPR1B O00238 8/20 0.59
ACVRL1 P37023 8/20 0.59
BMPR1A P36894 8/20 0.59
ACVR1B P36896 7/20 0.52
KDR P35968 5/20 0.50
TGFBR1 P36897 5/20 0.50
PRKAB1 Q9Y478 5/20 0.50
TGFBR2 P37173 4/20 0.50
BMPR2 Q13873 4/20 0.50
RET P07949 5/20 0.48
RIPK2 O43353 1/20 0.46
BMP4 P12644 1/20 0.46
ACVR2A P27037 1/20 0.46
ACVR2B Q13705 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17442042 0.95 ACVR1 (0.55) ACVR1BMPR1BACVRL1BMPR1AACVR1B
SCHEMBL17442205 0.93 ACVR1 (0.59) ACVR1BMPR1BACVRL1BMPR1AACVR1B
SCHEMBL17442431 0.92 ACVR1 (0.51) ACVR1BMPR1BACVRL1BMPR1AACVR1B
SCHEMBL17441823 0.92 ACVR1 (0.51) ACVR1BMPR1BACVRL1BMPR1AACVR1B
SCHEMBL16112017 0.91 BMPR1B (0.72) ACVR1BMPR1BACVRL1BMPR1AACVR1B
SCHEMBL17442356 0.91 ACVR1 (0.51) ACVR1BMPR1BACVRL1BMPR1AACVR1B
SCHEMBL16026088 0.88 ACVRL1 (0.66) ACVR1BMPR1BACVRL1BMPR1AACVR1B
SCHEMBL17442099 0.88 ACVR1 (0.55) ACVR1BMPR1BACVRL1BMPR1AACVR1B
SCHEMBL19123748 0.88 ACVR1 (0.49) ACVR1BMPR1BACVRL1BMPR1AACVR1B
SCHEMBL19123042 0.88 ACVR1 (0.52) ACVR1BMPR1BACVRL1BMPR1AACVR1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170197968-A1 Compositions and Methods for Inhibiting BMP NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2017-07-13 US disclosed
US-20170197968-A1 Compositions and Methods for Inhibiting BMP NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2017-07-13 US disclosed
WO-2016011019-A1 COMPOSITIONS AND METHODS FOR INHIBITING BMP THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) 2016-01-21 WO disclosed
WO-2016011019-A1 COMPOSITIONS AND METHODS FOR INHIBITING BMP THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) 2016-01-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170197968-A1 Compositions and Methods for Inhibiting BMP BMP1, BMP2, BMPR2 ACVR1 12/4885BMPR1B 8/4885ACVRL1 13/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.